Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 540-549

  Kaji, Kosuke ^a   Yoshiji, Hitoshi ^a   Kitade, Mitsuteru ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Shirai, Yusaku ^a   Yoshii, Junichi ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Yamazaki, Masaharu ^a   Tsujimoto, Tatsuhiro ^a   Kawaratani, Hideto ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiogenesis; Eplerenone; Hepatocellular carcinoma; Vascular endothelial growth factor

Indexed keywords

EPLERENONE; MITOGEN ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN;

ALLOGRAFT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL;

EID: 77954374234     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00636.x     Document Type: Article

References (48)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-17.
2. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-19.
3. Guo RP, Zhong C, Shi M. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2006, 132:547-55.
4. Iavarone M, Lampertico P, Iannuzzi F. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat 2007, 14:133-9.
5. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009, 50:604-20.
6. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69:4-10.
7. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19:6122-9.
8. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-27.
9. Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90.
10. Azad NS, Aragon-Ching JB, Dahut WL. Hand-foot reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:1411-16.
11. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004, 17:S16-20.
12. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007, 13:9-20.
13. Wolf G. Novel aspects of the renin-angiotensin-aldosterone-system. Front Biosci 2008, 13:4993-5005.
14. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003, 17:2061-7.
15. Herr D, Rodewald M, Fraser HM. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 2008, 109:418-25.
16. Herr D, Rodewald M, Fraser HM. Regulation of endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial cells. Reproduction 2008, 136:125-30.
17. Yoshiji H, Kuriyama S, Kawata M. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001, 7:1073-8.
18. Noguchi R, Yoshiji H, Kuriyama S. Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003, 9:6038-45.
19. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005, 10:7-13.
20. Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol 2009, 34:51-84.
21. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 2006, 47:609-13.
22. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008, 51:161-7.
23. Jeong Y, Chaupin DF, Matsushita K. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 2009, 106:3782-7.
24. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009, 104:124-33.
25. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-21.
26. Yoshiji H, Kuriyama S, Yoshii J. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998, 28:1489-96.
27. Rudolph AE, Rocha R, McMahon EG. Aldosterone target organ protein by eplerenone. Mol Cell Endocrinol 2004, 217:229-38.
28. McManus F, McInnes GT, Connell JM. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab 2008, 4:44-52.
29. Amaoka N, Saio M, Nonaka K. Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma. Oncol Rep 2006, 16:3-10.
30. Kojima H, Sakurai S, Yoshiji H, Uemura M, Yoshikawa M, Fukui H. The role of radixin in altered localization of canalicular conjugate export pump Mrp2 in cholestatic rat liver. Hepatol Res 2008, 38:202-10.
31. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001, 26:25-35.
32. Yoshiji H, Kuriyama S, Noguchi R. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol Res 2006, 36:124-9.
33. Yoshiji H, Kuriyama S, Noguchi R. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 2005, 42:687-93.
34. Cai J, Jiang WG, Ahmed A, Boulton M. Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc Res 2006, 71:20-31.
35. Oberleithner H, Ludwig T, Riethmuller C. Human endothelium: target for aldosterone. Hypertension 2004, 43:952-6.
36. Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 1996, 94:2566-71.
37. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008, 31:153-8.
38. Inai T, Mancuso M, Hashizume H. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
39. Ishizawa K, Izawa Y, Ito H. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005, 46:1046-52.
40. Nagai Y, Miyata K, Sun GP. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005, 46:1039-45.
41. Nishiyama A, Yao L, Fan Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005, 45:710-6.
42. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003, 5:408-17.
43. Montezano AC, Callera GE, Yogi A. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008, 28:1511-18.
44. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-36.
45. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphoryration and apoptosis in human 253-J B-V bladder cancer xenografts. Cancer Res 2004, 64:4601-10.
46. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005, 15:967-74.
47. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 2007, 104:967-72.
48. Yoshiji H, Noguchi R, Toyohara M. Combination of vitamin K(2) and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009, 51:315-21.